Getting your player ready...
Merck & Co. won U.S. regulatory clearance for its purchase of rival Schering-Plough Corp. after agreeing to sell its stake in the Merial Ltd. animal- health business and the nausea drug rolapitant.
Merck must divest the two assets to avoid becoming too dominant in the markets for animal-health and anti-nausea drugs, the Federal Trade Commission said Thursday.
